Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, Mumbai, Maharashtra, 400019, India.
Department of Biological Science and Biotechnology, Institute of Chemical Technology, Mumbai, Maharashtra, India.
Stem Cell Rev Rep. 2023 Nov;19(8):2650-2682. doi: 10.1007/s12015-023-10623-0. Epub 2023 Sep 14.
Maintenance of the visual function is the desired outcome of ophthalmologic therapies. The shortcomings of the current treatment options, like partial recovery, post-operation failure, rigorous post-operative care, complications, etc., which are usually encountered with the conventional treatment options has warranted newer treatment options that may eliminate the root cause of diseases and minimize the side effects. Cell therapies, a class of regenerative medicines, have emerged as cutting-edge treatment option. The corneal and retinal dystrophies during the ocular disorders are the major cause of blindness, worldwide. Corneal disorders are mainly categorized mainly into corneal epithelial, stromal, and endothelial disorders. On the other hand, glaucoma, retinitis pigmentosa, age-related macular degeneration, diabetic retinopathy, Stargardt Disease, choroideremia, Leber congenital amaurosis are then major retinal degenerative disorders. In this manuscript, we have presented a detailed overview of the development of cell-based therapies, using embryonic stem cells, bone marrow stem cells, mesenchymal stem cells, dental pulp stem cells, induced pluripotent stem cells, limbal stem cells, corneal epithelial, stromal and endothelial, embryonic stem cell-derived differentiated cells (like retinal pigment epithelium or RPE), neural progenitor cells, photoreceptor precursors, and bone marrow-derived hematopoietic stem/progenitor cells etc. The manuscript highlights their efficiency, drawbacks and the strategies that have been explored to regain visual function in the preclinical and clinical state associated with them which can be considered for their potential application in the development of treatment.
维持视觉功能是眼科治疗的理想效果。目前的治疗选择存在一些缺陷,如部分恢复、术后失败、严格的术后护理、并发症等,这些缺陷在常规治疗选择中经常出现,因此需要新的治疗选择,这些选择可能消除疾病的根本原因,并最大限度地减少副作用。细胞疗法是一类再生医学,已成为一种前沿治疗选择。眼部疾病中的角膜和视网膜变性是全球失明的主要原因。角膜疾病主要分为角膜上皮、基质和内皮疾病。另一方面,青光眼、色素性视网膜炎、年龄相关性黄斑变性、糖尿病性视网膜病变、Stargardt 病、脉络膜视网膜变性、莱伯先天性黑蒙是主要的视网膜退行性疾病。在本文中,我们详细介绍了基于细胞的疗法的发展,包括胚胎干细胞、骨髓干细胞、间充质干细胞、牙髓干细胞、诱导多能干细胞、角膜缘干细胞、角膜上皮、基质和内皮、胚胎干细胞衍生的分化细胞(如视网膜色素上皮或 RPE)、神经祖细胞、光感受器前体和骨髓来源的造血干细胞/祖细胞等。本文强调了它们的效率、缺点以及为恢复与之相关的临床前和临床状态下的视觉功能而探索的策略,这些策略可以考虑用于治疗的开发。